PerkinElmer and Vivascience/Sartorius to Develop Innovative Proteomics-Based Biomarker Platform.

BOSTON & HANNOVER, Germany -- PerkinElmer to Produce Proprietary, Integrated Reagent Platform for Biomarker Analysis

PerkinElmer Inc. (NYSE: PKI), a leading provider of drug discovery, life science research, and analytical solutions and Vivascience AG, a leading supplier of products and technology solutions for protein purification and analysis and member of the Sartorius Group, today announced that they have entered into a collaborative agreement in biomarker screening and discovery.

Under the terms of the agreement, Vivascience's patented membrane adsorber (MA) chromatography technology will be combined with PerkinElmer's proprietary elution chemistries to create fractionation kits for proteomics-based biomarker analysis. This reagent platform will be incorporated into PerkinElmer's integrated biomarker screening solution that includes automated sample preparation with the MultiPROBE(R) II liquid handling workstation and world-class biomarker detection with the prOTOF(TM) 2000 MALDI O-TOF mass spectrometer.

"By working with a market leader like Vivascience, we are able to accelerate bringing breakthrough innovations to the emerging markets of proteomics-based biomarker screening and discovery," said Peter Coggins, Ph.D., president of PerkinElmer Life and Analytical Sciences.

"We are excited to pair our unparalleled MA technology with PerkinElmer's extensive range of proteomics expertise," said Matthias Keff, CEO of Vivascience. "We are confident that the combined strength of PerkinElmer's state-of-the-art proteomic hardware and Vivascience's portfolio of membrane technology solutions will add significant value to the proteomics market."

PerkinElmer's biomarker screening solution is meeting with increasing excitement and acceptance in both the academic biomarker research community, as well as the emerging segment of biomarker-based research and diagnostic companies. For example, Kevin Rosenblatt, a leading researcher in Biomarker research and clinical proteomics at the University of Texas Southwestern, recently commented "The combination of ultra-high mass accuracy and superb resolution over a broad mass range in the prOTOF, coupled with an automated biomarker enrichment platform, make the PerkinElmer approach an ideal biomarker discovery and screening platform."

In addition, Guy della Cioppa, Senior Vice President of Business Development at Predictive Diagnostics, Inc (PDI) said "PDI is currently expanding its new facility and has adopted the PerkinElmer Biomarker Platform strategy as part of the development and implementation of new instrumentation and tools for its Clinical Proteomics Program." Recently, PDI, a leading clinical proteomics company in the field of predictive diagnostics, adopted the prOTOF as part of their BAMF(TM) in silico biomarker platform. They will have early access to the PerkinElmer/Vivascience fractionation kits through the end of the year.

Vivascience's unique MA technology, in contrast to traditional resins and beads, features a rigid format that makes it highly reproducible and robust. The technology also has significant ease-of-use advantages when incorporated into the PerkinElmer biomarker screening solution. The prOTOF 2000 is the cornerstone of the High Content Proteomics(TM) solution, a comprehensive approach to proteomics research pioneered by PerkinElmer. Using advanced, innovative technologies, like the prOTOF 2000 MALDI MS, PerkinElmer has developed a suite of tools that achieve maximum meaningful data from any sample, improving results and reproducibility.

PerkinElmer, Inc. is a global technology leader focused in the following businesses - Life and Analytical Sciences, Optoelectronics and Fluid Sciences. Combining operational excellence and technology expertise with an intimate understanding of our customers' needs, PerkinElmer provides products and services in health sciences and other advanced technology markets that require innovation, precision and reliability. The Company serves customers in more than 125 countries, and is a component of the S&P 500 Index. Additional information is available through www.perkinelmer.com or 1-877-PKI-NYSE.

Vivascience AG develops innovative solutions for protein purification and analysis with a product portfolio of device formats for filtration, ultrafiltration, and cell culture. Vivascience is a 100 percent owned subsidiary of Sartorius AG, Goettingen, an internationally leading laboratory and process technology supplier. In 2003, the technology group earned sales revenue of 442.3 million euros and employed a good 3,660 persons. Its biotechnology segment focuses on filtration and separation products, bioreactors and proteomics. The mechatronics segment manufactures weighing equipment and systems for laboratory and industrial applications.

BAMF is a registered trademark of Predictive Diagnostics, Inc. prOTOF is a trademark of MDS Sciex. All other trademarks are the property of PerkinElmer, Inc.

For more information, contact:

PerkinElmer Life and Analytical Sciences

549 Albany Street, Boston, MA, 02118, USA

Telephone: [phone] (U.S. Only) or [phone]

Fax: [phone]

Website: www.perkinelmer.com/lifesciences.

Factors Affecting Future Performance

This press release contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements contained in this press release that relate to prospective events or developments are deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "projects," "forecasts," "will" and similar expressions are intended to identify forward-looking statements. There are a number of important risk factors that could cause actual results or events to differ materially from those indicated by these forward-looking statements, including risks related to cyclical downturns affecting several of the industries into which we sell our products, our failure to introduce new products in a timely manner, the impact of our debt on our cash flow and investment opportunities, our ability to comply with financial covenants contained in our credit agreements and debt instruments, risks related to our international operations, our ability to adjust our operations to address unexpected changes, our ability to execute acquisitions and license technologies and successfully integrate acquired businesses and licensed technologies into our existing business, the loss of any of our licenses that may require us to stop selling products or lose competitive advantage, competition, regulatory changes, our failure to obtain and enforce intellectual property protection, our defense of third party claims of patent infringement and our ability to realize the full value of our intangible assets, as well as other factors which we describe under the caption "Forward-Looking Information and Factors Affecting Future Performance" in our most recently filed annual report on Form 10-K and in our most recently filed quarterly report on Form 10-Q. We disclaim any intention or obligation to update any forward-looking statements as a result of developments occurring after the date of this press release.